Related Experiment Video
Updated: May 11, 2026
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
Development of innovative paclitaxel-loaded small PLGA nanoparticles: study of their antiproliferative activity and
D Le Broc-Ryckewaert1, R Carpentier, E Lipka
1Université Lille Nord de France, F-59000 Lille, France.
Abstract:
Taxanes, including paclitaxel, are anti-cancer drugs approved for the treatment of prostate cancer but which have limited clinical application due to their hydrophobicity, their low therapeutic index and the emergence of chemoresistance. These side effects may be avoided through the use of new drug delivery systems such as nanoparticles, and paclitaxel-loaded PLGA nanoparticles up to 200 nm in size have shown encouraging results. As it is known that size affects the tissular penetration and distribution of tumors via the enhanced permeability and retention effect, so nanoparticles smaller than 100 nm are potentially interesting vehicles for improving paclitaxel delivery and efficacy. In this work, new paclitaxel-loaded small PLGA nanoparticles, between 49 nm and 95 nm in size and with positive or negative surface charges, were prepared without detergent. They were stable in the presence of serum, and HPLC showed that high paclitaxel loading and stability were achieved. Intracellular uptake of these nanoparticles was studied in PC3 cells by flow cytometry. Confocal studies confirmed a high tubulin destructuration at very low dose with these nanoparticles. This study suggests that both positively and negatively charged paclitaxel-loaded small PLGA nanoparticles deliver this drug into PC3 cells, and that this nanoparticle mode of delivery highly improves paclitaxel efficiency by up to two log-increase. These results also highlight the importance of small nanoparticles for drug delivery in cancer applications and are extremely promising for in vivo studies.
Insights
New, small poly(lactic-co-glycolic) acid (PLGA) nanoparticles effectively deliver paclitaxel, enhancing its anti-cancer efficacy against prostate cancer cells. These detergent-free nanoparticles show improved cellular uptake and tubulin disruption, promising for future cancer treatments.
Area of Science:
- Nanomedicine
- Materials Science
- Oncology
Background:
- Taxanes, like paclitaxel, are vital anti-cancer drugs for prostate cancer but face limitations due to hydrophobicity, low therapeutic index, and chemoresistance.
- Nanoparticle drug delivery systems, particularly poly(lactic-co-glycolic) acid (PLGA) nanoparticles, offer a promising strategy to overcome these limitations.
- Smaller nanoparticles (<100 nm) are hypothesized to improve tumor penetration and drug distribution via the enhanced permeability and retention effect.
Purpose of the Study:
- To develop and characterize novel, small paclitaxel-loaded PLGA nanoparticles (49-95 nm) without detergent.
- To evaluate the stability, drug loading, and serum stability of these nanoparticles.
- To assess the intracellular uptake and anti-cancer efficacy of these nanoparticles in PC3 prostate cancer cells.
Main Methods:
- Preparation of paclitaxel-loaded PLGA nanoparticles with varying sizes (49-95 nm) and surface charges (positive/negative) without detergent.
- High-Performance Liquid Chromatography (HPLC) for assessing paclitaxel loading and stability.
- Flow cytometry and confocal microscopy for evaluating intracellular uptake and tubulin destructuration in PC3 cells.
Main Results:
- Stable, detergent-free paclitaxel-loaded PLGA nanoparticles (49-95 nm) were successfully prepared with high drug loading and stability in serum.
- Significant intracellular uptake of nanoparticles by PC3 cells was confirmed via flow cytometry.
- Confocal studies demonstrated substantial tubulin destructuration at very low doses, indicating high drug efficacy.
- Paclitaxel delivery via these small nanoparticles resulted in a two-log increase in anti-cancer efficacy.
Conclusions:
- Both positively and negatively charged small PLGA nanoparticles effectively deliver paclitaxel into PC3 cells.
- This nanoparticle-mediated delivery significantly enhances paclitaxel's anti-cancer efficiency.
- The study underscores the importance of small nanoparticle size for improved drug delivery in cancer therapy and shows promise for in vivo applications.
